Certara, Inc. (CERT)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Do Nothing: liquidity and calendar filters pass, but CERT's technical score is 3/5 and the chart has not confirmed a tradable bullish setup. Price is still pinned beneath the SMA20/SMA50 and daily VWAP resistance cluster, with lighter recent volume, so there is no clean long trigger today.
Company overview
Certara, Inc. provides software solutions and services for biosimulation across the drug development lifecycle, from drug discovery to market entry. The company offers mechanistic and empirical biosimulation, regulatory guidance, and market access consultation. Its clients include biopharmaceutical firms, academic institutions, and governmental organizations.
Fundamental
fairCertara shows steady revenue growth and strong cash flow but inconsistent GAAP profitability and mixed risk indicators.
Mixed fundamentals: revenue compounded at ~10.00% (FY 2021–2025) and FY 2025 operating cash flow was about $96M, but trailing profitability remains weak (TTM net margin ~-3.60%, ROE ~-1.43%) and Altman Z-Score is ~1.66 (distress zone). SEC filings indicate manageable liquidity and covenant compliance (Q1 2026 cash ~$149.5M vs term-loan debt ~$294.8M) alongside buybacks and a divestiture that adds cash. Valuation is reasonable on EV/EBITDA (~11.92) and free-cash-flow yield (~7.84%), but risk/returns keep the score at 3.
Sentiment
fairSentiment is mildly negative due to CFO transition uncertainty and negative media coverage.
A fresh bullish product headline (Certara’s announced NVIDIA BioNeMo Agent Toolkit integration on 2026-07-07) is arriving into still-cautious sentiment where recent coverage is dominated by plaintiff-law-firm “investigation” noise; the 30–90d baseline remained bearish after the Q1 earnings miss. Legal scan found no regulator-confirmed investigation (overhang is solicitation-driven), so the setup is forming rather than fully confirmed.
Technical
fairThe chart shows short-term support but remains under broader trend resistance, suggesting patience over a fresh long entry.
The chart has repaired some short-term damage after the 6/16 spike by holding the 5.31-5.40 support band and staying marginally above EMA9 and EMA21, while RSI has normalized and the MACD histogram has turned slightly positive. But price is still under the SMA20/SMA50/SMA200 stack and just under daily VWAP, and recent participation has cooled, so the evidence supports patience rather than a fresh long entry.
You’re looking at 2026-06-25 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.